Gavril W. Pasternak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gavril W. Pasternak has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Susruta Majumdar
Molecular Pharmacology Program and Department of Neurology, Memorial Sloan Kettering Cancer Centre, New York, USA; Center for Clinical Pharmacology, St Louis College of Pharmacy and Washington University School of Medicine, St Louis, MO, USA
12 shared publications- Ying-Xian Pan
Department of Anesthesiology, Rutgers New Jersey Medical School, Newark, NJ 07103, USA
12 shared publications Jin Xu
From the Department of Neurology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
11 shared publicationsYing-Xian Pan
From the Department of Neurology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
11 shared publications- Steven G. Grinnell
Bristol Myers Squibb
8 shared publications Valerie Le Rouzic
Department of Neurology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
7 shared publications
Latest Publications
- Open Access
- 31 October 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 41 (5) , 1075
Correction to: Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1
The original version of this article unfortunately contained a typo in co-author name.
- 31 October 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 41 (5) , 1075
Open AccessCorrection to: Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1
The original version of this article unfortunately contained a typo in co-author name.
- 8 October 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 41 (5) , 1059-1074
Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1
The biased signaling has been extensively studied in the original mu opioid receptor (MOR-1), particularly through G protein and β-arrestin2 signaling pathways. The concept that the G protein pathway is often linked to the therapeutic effect of the drug, while the β-arrestin pathway is associated to the side effects has been proposed to develop biased analgesic compounds with limited side-effects associated with traditional opiates. The mu opioid receptor gene, OPRM1, undergoes extensive alternative pre-mRNA splicing, generating multiple splice variants or isoforms that are conserved from rodent to human. One type of the Oprm1 splice variants are the full-length 7 transmembrane (7TM) C-terminal splice variants, which have identical receptor structures including entire binding pocket, but contain a different intracellular C-terminal tail resulted from 3′ alternative splicing. Increasing evidence suggest that these full-length 7TM C-terminal variants play important roles in mu opioid pharmacology, raising questions regarding biased signaling at these multiple C-terminal variants. In the present study, we investigated the effect of different C-terminal variants on mu agonist-induced G protein coupling, β-arrestin2 recruitment, and ultimately, signaling bias. We found that mu agonists produced marked differences in G protein activation and β-arrestin2 recruitment among various C-terminal variants, leading to biased signaling at various level. Particularly, MOR-1O, an exon 7-associated variant, showed greater β-arrestin2 bias for most mu agonists than MOR-1, an exon 4-associated variant. Biased signaling of G protein-coupled receptors has been defined by evidences that different agonists can produce divergent signaling transduction pathways through a single receptor. Our findings that a single mu agonist can induce differential signaling through multiple 7TM splice variants provide a new perspective on biased signaling at least for Oprm1, which perhaps is important for our understanding of the complex mu opioid actions in vivo where all the 7TM splice variants co-exist.
- 8 October 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 41 (5) , 1059-1074
Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1
The biased signaling has been extensively studied in the original mu opioid receptor (MOR-1), particularly through G protein and β-arrestin2 signaling pathways. The concept that the G protein pathway is often linked to the therapeutic effect of the drug, while the β-arrestin pathway is associated to the side effects has been proposed to develop biased analgesic compounds with limited side-effects associated with traditional opiates. The mu opioid receptor gene, OPRM1, undergoes extensive alternative pre-mRNA splicing, generating multiple splice variants or isoforms that are conserved from rodent to human. One type of the Oprm1 splice variants are the full-length 7 transmembrane (7TM) C-terminal splice variants, which have identical receptor structures including entire binding pocket, but contain a different intracellular C-terminal tail resulted from 3′ alternative splicing. Increasing evidence suggest that these full-length 7TM C-terminal variants play important roles in mu opioid pharmacology, raising questions regarding biased signaling at these multiple C-terminal variants. In the present study, we investigated the effect of different C-terminal variants on mu agonist-induced G protein coupling, β-arrestin2 recruitment, and ultimately, signaling bias. We found that mu agonists produced marked differences in G protein activation and β-arrestin2 recruitment among various C-terminal variants, leading to biased signaling at various level. Particularly, MOR-1O, an exon 7-associated variant, showed greater β-arrestin2 bias for most mu agonists than MOR-1, an exon 4-associated variant. Biased signaling of G protein-coupled receptors has been defined by evidences that different agonists can produce divergent signaling transduction pathways through a single receptor. Our findings that a single mu agonist can induce differential signaling through multiple 7TM splice variants provide a new perspective on biased signaling at least for Oprm1, which perhaps is important for our understanding of the complex mu opioid actions in vivo where all the 7TM splice variants co-exist.
- 18 May 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 41 (5) , 977-993
Synthesis and Characterization of Azido Aryl Analogs of IBNtxA for Radio-Photoaffinity Labeling Opioid Receptors in Cell Lines and in Mouse Brain
Mu opioid receptors (MOR-1) mediate the biological actions of clinically used opioids such as morphine, oxycodone, and fentanyl. The mu opioid receptor gene, OPRM1, undergoes extensive alternative splicing, generating multiple splice variants. One type of splice variants are truncated variants containing only six transmembrane domains (6TM) that mediate the analgesic action of novel opioid drugs such as 3′-iodobenzoylnaltrexamide (IBNtxA). Previously, we have shown that IBNtxA is a potent analgesic effective in a spectrum of pain models but lacks many side-effects associated with traditional opiates. In order to investigate the targets labeled by IBNtxA, we synthesized two arylazido analogs of IBNtxA that allow photolabeling of mouse mu opioid receptors (mMOR-1) in transfected cell lines and mMOR-1 protein complexes that may comprise the 6TM sites in mouse brain. We demonstrate that both allyl and alkyne arylazido derivatives of IBNtxA efficiently radio-photolabeled mMOR-1 in cell lines and MOR-1 protein complexes expressed either exogenously or endogenously, as well as found in mouse brain. In future, design and application of such radio-photolabeling ligands with a conjugated handle will provide useful tools for further isolating or purifying MOR-1 to investigate site specific ligand–protein contacts and its signaling complexes.
- 18 May 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 41 (5) , 977-993
Synthesis and Characterization of Azido Aryl Analogs of IBNtxA for Radio-Photoaffinity Labeling Opioid Receptors in Cell Lines and in Mouse Brain
Mu opioid receptors (MOR-1) mediate the biological actions of clinically used opioids such as morphine, oxycodone, and fentanyl. The mu opioid receptor gene, OPRM1, undergoes extensive alternative splicing, generating multiple splice variants. One type of splice variants are truncated variants containing only six transmembrane domains (6TM) that mediate the analgesic action of novel opioid drugs such as 3′-iodobenzoylnaltrexamide (IBNtxA). Previously, we have shown that IBNtxA is a potent analgesic effective in a spectrum of pain models but lacks many side-effects associated with traditional opiates. In order to investigate the targets labeled by IBNtxA, we synthesized two arylazido analogs of IBNtxA that allow photolabeling of mouse mu opioid receptors (mMOR-1) in transfected cell lines and mMOR-1 protein complexes that may comprise the 6TM sites in mouse brain. We demonstrate that both allyl and alkyne arylazido derivatives of IBNtxA efficiently radio-photolabeled mMOR-1 in cell lines and MOR-1 protein complexes expressed either exogenously or endogenously, as well as found in mouse brain. In future, design and application of such radio-photolabeling ligands with a conjugated handle will provide useful tools for further isolating or purifying MOR-1 to investigate site specific ligand–protein contacts and its signaling complexes.
- Top Cited PapersOpen Access
- 29 May 2019
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 5 (6) , 992-1001
7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects
Mitragyna speciosa, more commonly known as kratom, is a plant native to Southeast Asia, the leaves of which have been used traditionally as a stimulant, analgesic, and treatment for opioid addiction. Recently, growing use of the plant in the United States and concerns that kratom represents an uncontrolled drug with potential abuse liability, have highlighted the need for more careful study of its pharmacological activity. The major active alkaloid found in kratom, mitragynine, has been reported to have opioid agonist and analgesic activity in vitro and in animal models, consistent with the purported effects of kratom leaf in humans. However, preliminary research has provided some evidence that mitragynine and related compounds may act as atypical opioid agonists, inducing therapeutic effects such as analgesia, while limiting the negative side effects typical of classical opioids. Here we report evidence that an active metabolite plays an important role in mediating the analgesic effects of mitragynine. We find that mitragynine is converted in vitro in both mouse and human liver preparations to the much more potent mu-opioid receptor agonist 7-hydroxymitragynine and that this conversion is mediated by cytochrome P450 3A isoforms. Further, we show that 7-hydroxymitragynine is formed from mitragynine in mice and that brain concentrations of this metabolite are sufficient to explain most or all of the opioid-receptor-mediated analgesic activity of mitragynine. At the same time, mitragynine is found in the brains of mice at very high concentrations relative to its opioid receptor binding affinity, suggesting that it does not directly activate opioid receptors. The results presented here provide a metabolism-dependent mechanism for the analgesic effects of mitragynine and clarify the importance of route of administration for determining the activity of this compound. Further, they raise important questions about the interpretation of existing data on mitragynine and highlight critical areas for further research in animals and humans.
- 29 May 2019
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 5 (6) , 992-1001
Top Cited PapersOpen Access7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects
Mitragyna speciosa, more commonly known as kratom, is a plant native to Southeast Asia, the leaves of which have been used traditionally as a stimulant, analgesic, and treatment for opioid addiction. Recently, growing use of the plant in the United States and concerns that kratom represents an uncontrolled drug with potential abuse liability, have highlighted the need for more careful study of its pharmacological activity. The major active alkaloid found in kratom, mitragynine, has been reported to have opioid agonist and analgesic activity in vitro and in animal models, consistent with the purported effects of kratom leaf in humans. However, preliminary research has provided some evidence that mitragynine and related compounds may act as atypical opioid agonists, inducing therapeutic effects such as analgesia, while limiting the negative side effects typical of classical opioids. Here we report evidence that an active metabolite plays an important role in mediating the analgesic effects of mitragynine. We find that mitragynine is converted in vitro in both mouse and human liver preparations to the much more potent mu-opioid receptor agonist 7-hydroxymitragynine and that this conversion is mediated by cytochrome P450 3A isoforms. Further, we show that 7-hydroxymitragynine is formed from mitragynine in mice and that brain concentrations of this metabolite are sufficient to explain most or all of the opioid-receptor-mediated analgesic activity of mitragynine. At the same time, mitragynine is found in the brains of mice at very high concentrations relative to its opioid receptor binding affinity, suggesting that it does not directly activate opioid receptors. The results presented here provide a metabolism-dependent mechanism for the analgesic effects of mitragynine and clarify the importance of route of administration for determining the activity of this compound. Further, they raise important questions about the interpretation of existing data on mitragynine and highlight critical areas for further research in animals and humans.
- 1 May 2019
- Published by Elsevier in Neuropharmacology
- Vol. 150, 217-228
MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats
- 1 May 2019
- Published by Elsevier in Neuropharmacology
- Vol. 150, 217-228
MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats
- 1 February 2019
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 128 (2) , 365-373
Pharmacological Characterization of Levorphanol, a G-Protein Biased Opioid Analgesic
BACKGROUND: Levorphanol is a potent analgesic that has been used for decades. Most commonly used for acute and cancer pain, it also is effective against neuropathic pain. The recent appreciation of the importance of functional bias and the uncovering of multiple µ opioid receptor splice variants may help explain the variability of patient responses to different opioid drugs.METHODS: Here, we evaluate levorphanol in a variety of traditional in vitro receptor binding and functional assays. In vivo analgesia studies using the radiant heat tail flick assay explored the receptor selectivity of the responses through the use of knockout (KO) mice, selective antagonists, and viral rescue approaches.RESULTS: Receptor binding studies revealed high levorphanol affinity for all the μ, δ, and κ opioid receptors. In35S-GTPγS binding assays, it was a full agonist at most µ receptor subtypes, with the exception of MOR-1O, but displayed little activity in β-arrestin2 recruitment assays, indicating a preference for G-protein transduction mechanisms. A KO mouse and selective antagonists confirmed that levorphanol analgesia was mediated through classical µ receptors, but there was a contribution from 6 transmembrane targets, as illustrated by a lower response in an exon 11 KO mouse and its rescue with a virally transfected 6 transmembrane receptor splice variant. Compared to morphine, levorphanol had less respiratory depression at equianalgesic doses.CONCLUSIONS: While levorphanol shares many of the same properties as the classic opioid morphine, it displays subtle differences that may prove helpful in its clinical use. Its G-protein signaling bias is consistent with its diminished respiratory depression, while its incomplete cross tolerance with morphine suggests it may prove valuable clinically with opioid rotation.
- 1 February 2019
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 128 (2) , 365-373
Pharmacological Characterization of Levorphanol, a G-Protein Biased Opioid Analgesic
BACKGROUND: Levorphanol is a potent analgesic that has been used for decades. Most commonly used for acute and cancer pain, it also is effective against neuropathic pain. The recent appreciation of the importance of functional bias and the uncovering of multiple µ opioid receptor splice variants may help explain the variability of patient responses to different opioid drugs.METHODS: Here, we evaluate levorphanol in a variety of traditional in vitro receptor binding and functional assays. In vivo analgesia studies using the radiant heat tail flick assay explored the receptor selectivity of the responses through the use of knockout (KO) mice, selective antagonists, and viral rescue approaches.RESULTS: Receptor binding studies revealed high levorphanol affinity for all the μ, δ, and κ opioid receptors. In35S-GTPγS binding assays, it was a full agonist at most µ receptor subtypes, with the exception of MOR-1O, but displayed little activity in β-arrestin2 recruitment assays, indicating a preference for G-protein transduction mechanisms. A KO mouse and selective antagonists confirmed that levorphanol analgesia was mediated through classical µ receptors, but there was a contribution from 6 transmembrane targets, as illustrated by a lower response in an exon 11 KO mouse and its rescue with a virally transfected 6 transmembrane receptor splice variant. Compared to morphine, levorphanol had less respiratory depression at equianalgesic doses.CONCLUSIONS: While levorphanol shares many of the same properties as the classic opioid morphine, it displays subtle differences that may prove helpful in its clinical use. Its G-protein signaling bias is consistent with its diminished respiratory depression, while its incomplete cross tolerance with morphine suggests it may prove valuable clinically with opioid rotation.
- 11 October 2018
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 25 (11) , 992-993
σ1 Receptor ligand binding: an open-and-shut case
- 11 October 2018
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 25 (11) , 992-993
σ1 Receptor ligand binding: an open-and-shut case
- Open Access
- 21 November 2017
- Published by H1 Connect
Faculty Opinions recommendation of Bias factor and therapeutic window correlate to predict safer opioid analgesics.
In this paper, the authors provide a detailed validation of the role of bias in opioid actions, demonstrating a decrease in side-effect profiles with increasing G-protein bias. This is a significant step forward in that it provides a solid foundation in support of the premise first put forward by this group almost 20 years ago.
- 21 November 2017
- Published by H1 Connect
Open AccessFaculty Opinions recommendation of Bias factor and therapeutic window correlate to predict safer opioid analgesics.
In this paper, the authors provide a detailed validation of the role of bias in opioid actions, demonstrating a decrease in side-effect profiles with increasing G-protein bias. This is a significant step forward in that it provides a solid foundation in support of the premise first put forward by this group almost 20 years ago.
- 1 July 2017
- Published by Springer Nature
- Vol. 244, 163-175
Allosteric Modulation of Opioid G-Protein Coupled Receptors by Sigma1 Receptors
Since their proposal in 1976, the concept of sigma1 receptors has been continually evolving. Initially thought to be a member of the opioid receptor family, molecular studies have now identified its genes and established its structure crystallographically. Much effort has now revealed its importance as a chaperone in the endoplasmic reticulum, but its functions extend beyond this. Sigma1 receptors have been associated with a host of signaling systems. Evidence over the past 20 years has established the modulatory effects of sigma1 ligands on opioid systems. Despite their inability to bind directly to opioid receptors, sigma1 ligands can modulate opioid analgesia in vivo and signal transduction mechanisms in vitro. Furthermore, sigma1 receptors can physically associate with GPCRs. Together, these findings show that sigma1 ligands can function as allosteric modulators of GPCR function through their association with the sigma1 receptors, which are in direct physical association with opioid receptors, members of the G-protein coupled family of receptors.
- 1 July 2017
- Published by Springer Nature
- Vol. 244, 163-175
Allosteric Modulation of Opioid G-Protein Coupled Receptors by Sigma1 Receptors
Since their proposal in 1976, the concept of sigma1 receptors has been continually evolving. Initially thought to be a member of the opioid receptor family, molecular studies have now identified its genes and established its structure crystallographically. Much effort has now revealed its importance as a chaperone in the endoplasmic reticulum, but its functions extend beyond this. Sigma1 receptors have been associated with a host of signaling systems. Evidence over the past 20 years has established the modulatory effects of sigma1 ligands on opioid systems. Despite their inability to bind directly to opioid receptors, sigma1 ligands can modulate opioid analgesia in vivo and signal transduction mechanisms in vitro. Furthermore, sigma1 receptors can physically associate with GPCRs. Together, these findings show that sigma1 ligands can function as allosteric modulators of GPCR function through their association with the sigma1 receptors, which are in direct physical association with opioid receptors, members of the G-protein coupled family of receptors.
- Open Access
- 23 June 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (27) , 6888-6890
Cloning the sigma2receptor: Wandering 40 years to find an identity
Scientists have endeavored to understand sigma receptors for over 40 y. Although most agree that they are important, there is little agreement on anything else. In their behavioral classification of opioid receptors in 1976, Martin et al. (1) proposed three groups of compounds illustrating three distinct opioid receptor classes (mu, kappa, and sigma) based upon morphine, ketocyclazocine, and SKF10,047, respectively, and noted that the opioid antagonist naltrexone antagonized them all. Since then, the sigma receptor story has undergone many twists and turns. Although the SKF10,047 stereoisomer used in the initial description is not stated, subsequent investigators used (+)SKF10,047 to define sigma receptors, identifying sites that clearly were not opioid. Extensive binding studies associated (+)SKF10,047 with many putative receptors, including phencyclidine (2), but these ligands proved quite promiscuous, labeling a multitude of sites. As more ligands became available, sigma receptors were dissociated into two categories: sigma1 and sigma2 (3). Functional studies strongly suggested that both classes were important. Our understanding of sigma1 receptors took a major leap forward with the cloning of the protein in 1996 (4) and its subsequent crystallization in 2016 (5). However, these structural insights have not answered many fundamental questions regarding how these proteins work. In PNAS, Alon et al. (6) present compelling information for the cloning of the sigma2 receptor, completing the molecular characterization of this class of receptor and …
- 23 June 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (27) , 6888-6890
Open AccessCloning the sigma2receptor: Wandering 40 years to find an identity
Scientists have endeavored to understand sigma receptors for over 40 y. Although most agree that they are important, there is little agreement on anything else. In their behavioral classification of opioid receptors in 1976, Martin et al. (1) proposed three groups of compounds illustrating three distinct opioid receptor classes (mu, kappa, and sigma) based upon morphine, ketocyclazocine, and SKF10,047, respectively, and noted that the opioid antagonist naltrexone antagonized them all. Since then, the sigma receptor story has undergone many twists and turns. Although the SKF10,047 stereoisomer used in the initial description is not stated, subsequent investigators used (+)SKF10,047 to define sigma receptors, identifying sites that clearly were not opioid. Extensive binding studies associated (+)SKF10,047 with many putative receptors, including phencyclidine (2), but these ligands proved quite promiscuous, labeling a multitude of sites. As more ligands became available, sigma receptors were dissociated into two categories: sigma1 and sigma2 (3). Functional studies strongly suggested that both classes were important. Our understanding of sigma1 receptors took a major leap forward with the cloning of the protein in 1996 (4) and its subsequent crystallization in 2016 (5). However, these structural insights have not answered many fundamental questions regarding how these proteins work. In PNAS, Alon et al. (6) present compelling information for the cloning of the sigma2 receptor, completing the molecular characterization of this class of receptor and …